DOES REVISED INTERNATIONAL PROGNOSITIC SCORING SYSTEM (IPSS-R) HAVE ANY IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS?

被引：0
|
作者：
Teo, Z. [1 ]
Yiu, R. [1 ]
Yueh, L. Ling [1 ]
Ho, A. [1 ]
机构：
[1] Singapore Gen Hosp, Singhlth, Haematol, Singapore, Singapore
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P747
引用
收藏
页码：312 / 313
页数：2
相关论文
共 50 条
  • [21] Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
    Mishra, Asmita
    Corrales-Yepez, Maria
    Al Ali, Najla
    Kharfan-Dabaja, Mohamed
    Padron, Eric
    Zhang, Ling
    Epling-Burnette, Pearlie K.
    Pinilla-Ibarz, Javier
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (07) : 566 - 570
  • [22] Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes (MDS): Ramifications for the Current Practice of Bone Marrow (BM) Manual Differential Count
    Nguyen, P. L.
    Cioc, A.
    Fonstad, R.
    Roesler, M. A.
    Hirsch, B.
    Warlick, E. D.
    Ross, J. A.
    LABORATORY INVESTIGATION, 2014, 94 : 364A - 364A
  • [23] CYTOGENETIC CATEGORIES OF MYELODYSPLASTIC SYNDROMES (MDS) ACCORDING TO REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (R-IPSS)
    Gritsaev, S.
    Martinkevitch, I.
    Petrova, E.
    Kostroma, I.
    Ivanova, M.
    Martinenko, L.
    Sergeev, A.
    Abdukkadirov, K.
    HAEMATOLOGICA, 2012, 97 : 578 - 578
  • [24] Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
    Kewan, Tariq
    Bewersdorf, Jan Philipp
    Blaha, Ondrej
    Stahl, Maximilian
    Ali, Najla Hal
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    Amaya, Maria L.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Logothetis, Constantine
    Ramaswamy, Rahul
    Rose, Ameera
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Shallis, Rory M.
    Xie, Zhuoer
    Padron, Eric
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [25] Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
    de Swart, Louise
    Smith, Alex
    Johnston, Thomas W.
    Haase, Detlef
    Droste, Jackie
    Fenaux, Pierre
    Symeonidis, Argiris
    Sanz, Guillermo
    Hellstroem-Lindberg, Eva
    Cermak, Jaroslav
    Germing, Ulrich
    Stauder, Reinhard
    Georgescu, Otilia
    MacKenzie, Marius
    Malcovati, Luca
    Holm, Mette S.
    Almeida, Antonio M.
    Madry, Krzysztof
    Slama, Borhane
    Guerci-Bresler, Agnes
    Sanhes, Laurence
    Beyne-Rauzy, Odile
    Luno, Elisa
    Bowen, David
    de Witte, Theo
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 372 - 383
  • [26] Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R)
    Della Porta, Matteo Giovanni
    Alessandrino, Emilio Paolo
    Jackson, Christopher H.
    Pascutto, Cristiana
    Bacigalupo, Andrea
    Malcovati, Luca
    Van Lint, Maria Teresa
    Allione, Bernardino
    Bernardi, Massimo
    Onida, Francesco
    Guidi, Stefano
    Iori, Anna Paola
    Cerretti, Raffaella
    Marenco, Paola
    Pioltelli, Pietro
    Angelucci, Emanuele
    Bosi, Alberto
    Cazzola, Mario
    Rambaldi, Alessandro
    BLOOD, 2014, 124 (21)
  • [27] Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes
    Zeidan, Amer M.
    Klink, Andrew J.
    McGuire, Michael
    Feinberg, Bruce
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 2050 - 2055
  • [28] The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS)
    Nazha, Aziz
    Narkhede, Mayur Subhash
    Radivoyevitch, Tomas
    Kalaycio, Matt
    Patel, Bhumika J.
    Gerds, Aaron T.
    Mukherjee, Sudipto
    Clemente, Michael
    Hirsch, Cassandra M.
    Advani, Anjali S.
    Przychodzen, Bartlomiej
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [29] Implications of Using the Revised International Prognostic Scoring System (IPSS-R) for Patients with Therapy-Related Neoplasms
    Ok, C. Y.
    Zuo, Z.
    Garcia-Manero, G.
    Medeiros, L. J.
    Wang, S. A.
    MODERN PATHOLOGY, 2013, 26 : 354A - 354A
  • [30] Implications of Using the Revised International Prognostic Scoring System (IPSS-R) for Patients with Therapy-Related Neoplasms
    Ok, C. Y.
    Zuo, Z.
    Garcia-Manero, G.
    Medeiros, L. J.
    Wang, S. A.
    LABORATORY INVESTIGATION, 2013, 93 : 354A - 354A
12345